Progesterone metabolite allopregnanolone in women with premenstrual syndrome

Andrea J. Rapkin, Melinda Morgan, Linda Goldman, Darrell W Brann, Deborah Simone, Virendra B. Mahesh

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

Objective: To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual syndrome (PMS) and controls. Methods: Thirty-five women with prospectively documented PMS and 36 controls were evaluated. Serum progesterone and allopregnanolone levels were measured on days 19 and 26 of the cycle as determined by urinary LH detection kits. Analysis of variance and Student t tests were used to analyze the data. Results: Allopregnanolone levels were significantly lower on day 26 in the PMS group than in controls (3.6 ± 0.8 versus 7.5 ± 1.3 ng/mL; P < .04). Significant differences in the ratio of the metabolite to progesterone also were noted, with a smaller ratio in the PMS subjects (0.9 ± 0.3 versus 3.2 ± 1.3 ng/mL; P < .05). There were no significant differences between the PMS and control groups with respect to serum progesterone levels. Conclusion: Subjects with PMS manifested lower levels of the anxiolytic metabolite allopregnanolone in the luteal phase when compared with controls. Diminished concentrations of allopregnanolone in women with PMS may lead to an inability to enhance gamma aminobutyric acid- mediated inhibition during states of altered central nervous system excitability, such as ovulation or physiologic or psychological stress. The lowered metabolite levels could contribute to the genesis of various mood symptoms of the disorder, such as anxiety, tension, and depression.

Original languageEnglish (US)
Pages (from-to)709-714
Number of pages6
JournalObstetrics and Gynecology
Volume90
Issue number5
DOIs
StatePublished - Nov 1 1997

Fingerprint

Pregnanolone
Premenstrual Syndrome
Progesterone
Luteal Phase
Anti-Anxiety Agents
Control Groups
Ovulation
Serum
Mood Disorders
Psychological Stress
gamma-Aminobutyric Acid
Analysis of Variance
Anxiety
Central Nervous System
Depression
Students

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Progesterone metabolite allopregnanolone in women with premenstrual syndrome. / Rapkin, Andrea J.; Morgan, Melinda; Goldman, Linda; Brann, Darrell W; Simone, Deborah; Mahesh, Virendra B.

In: Obstetrics and Gynecology, Vol. 90, No. 5, 01.11.1997, p. 709-714.

Research output: Contribution to journalArticle

Rapkin, Andrea J. ; Morgan, Melinda ; Goldman, Linda ; Brann, Darrell W ; Simone, Deborah ; Mahesh, Virendra B. / Progesterone metabolite allopregnanolone in women with premenstrual syndrome. In: Obstetrics and Gynecology. 1997 ; Vol. 90, No. 5. pp. 709-714.
@article{a18739733f134819992d117d54360903,
title = "Progesterone metabolite allopregnanolone in women with premenstrual syndrome",
abstract = "Objective: To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual syndrome (PMS) and controls. Methods: Thirty-five women with prospectively documented PMS and 36 controls were evaluated. Serum progesterone and allopregnanolone levels were measured on days 19 and 26 of the cycle as determined by urinary LH detection kits. Analysis of variance and Student t tests were used to analyze the data. Results: Allopregnanolone levels were significantly lower on day 26 in the PMS group than in controls (3.6 ± 0.8 versus 7.5 ± 1.3 ng/mL; P < .04). Significant differences in the ratio of the metabolite to progesterone also were noted, with a smaller ratio in the PMS subjects (0.9 ± 0.3 versus 3.2 ± 1.3 ng/mL; P < .05). There were no significant differences between the PMS and control groups with respect to serum progesterone levels. Conclusion: Subjects with PMS manifested lower levels of the anxiolytic metabolite allopregnanolone in the luteal phase when compared with controls. Diminished concentrations of allopregnanolone in women with PMS may lead to an inability to enhance gamma aminobutyric acid- mediated inhibition during states of altered central nervous system excitability, such as ovulation or physiologic or psychological stress. The lowered metabolite levels could contribute to the genesis of various mood symptoms of the disorder, such as anxiety, tension, and depression.",
author = "Rapkin, {Andrea J.} and Melinda Morgan and Linda Goldman and Brann, {Darrell W} and Deborah Simone and Mahesh, {Virendra B.}",
year = "1997",
month = "11",
day = "1",
doi = "10.1016/S0029-7844(97)00417-1",
language = "English (US)",
volume = "90",
pages = "709--714",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Progesterone metabolite allopregnanolone in women with premenstrual syndrome

AU - Rapkin, Andrea J.

AU - Morgan, Melinda

AU - Goldman, Linda

AU - Brann, Darrell W

AU - Simone, Deborah

AU - Mahesh, Virendra B.

PY - 1997/11/1

Y1 - 1997/11/1

N2 - Objective: To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual syndrome (PMS) and controls. Methods: Thirty-five women with prospectively documented PMS and 36 controls were evaluated. Serum progesterone and allopregnanolone levels were measured on days 19 and 26 of the cycle as determined by urinary LH detection kits. Analysis of variance and Student t tests were used to analyze the data. Results: Allopregnanolone levels were significantly lower on day 26 in the PMS group than in controls (3.6 ± 0.8 versus 7.5 ± 1.3 ng/mL; P < .04). Significant differences in the ratio of the metabolite to progesterone also were noted, with a smaller ratio in the PMS subjects (0.9 ± 0.3 versus 3.2 ± 1.3 ng/mL; P < .05). There were no significant differences between the PMS and control groups with respect to serum progesterone levels. Conclusion: Subjects with PMS manifested lower levels of the anxiolytic metabolite allopregnanolone in the luteal phase when compared with controls. Diminished concentrations of allopregnanolone in women with PMS may lead to an inability to enhance gamma aminobutyric acid- mediated inhibition during states of altered central nervous system excitability, such as ovulation or physiologic or psychological stress. The lowered metabolite levels could contribute to the genesis of various mood symptoms of the disorder, such as anxiety, tension, and depression.

AB - Objective: To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual syndrome (PMS) and controls. Methods: Thirty-five women with prospectively documented PMS and 36 controls were evaluated. Serum progesterone and allopregnanolone levels were measured on days 19 and 26 of the cycle as determined by urinary LH detection kits. Analysis of variance and Student t tests were used to analyze the data. Results: Allopregnanolone levels were significantly lower on day 26 in the PMS group than in controls (3.6 ± 0.8 versus 7.5 ± 1.3 ng/mL; P < .04). Significant differences in the ratio of the metabolite to progesterone also were noted, with a smaller ratio in the PMS subjects (0.9 ± 0.3 versus 3.2 ± 1.3 ng/mL; P < .05). There were no significant differences between the PMS and control groups with respect to serum progesterone levels. Conclusion: Subjects with PMS manifested lower levels of the anxiolytic metabolite allopregnanolone in the luteal phase when compared with controls. Diminished concentrations of allopregnanolone in women with PMS may lead to an inability to enhance gamma aminobutyric acid- mediated inhibition during states of altered central nervous system excitability, such as ovulation or physiologic or psychological stress. The lowered metabolite levels could contribute to the genesis of various mood symptoms of the disorder, such as anxiety, tension, and depression.

UR - http://www.scopus.com/inward/record.url?scp=0030762277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030762277&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(97)00417-1

DO - 10.1016/S0029-7844(97)00417-1

M3 - Article

C2 - 9351749

AN - SCOPUS:0030762277

VL - 90

SP - 709

EP - 714

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -